Medications
Nutrition guidance for
every GLP-1 medication.
Each medication has its own pharmacology, side-effect profile, and dose schedule. So does its nutrition strategy. Pick yours below.
Mounjaro
tirzepatide · Once-weekly subcutaneous injection
Mounjaro is a once-weekly injectable for adults with type 2 diabetes. The active ingredient, tirzepatide, is the first dual GLP-1/GIP receptor agonist — it activates BOTH gut hormone receptors involved in glucose and appetite regulation. This dual action makes it more potent than semaglutide-based drugs (Ozempic, Wegovy).
Read nutrition guide →
Ozempic
semaglutide · Once-weekly subcutaneous injection
Ozempic is a once-weekly injectable medication for adults with type 2 diabetes. The active ingredient, semaglutide, is a GLP-1 receptor agonist — it mimics a hormone your gut produces after eating. Although Ozempic is FDA-approved for blood sugar control, it's widely prescribed off-label for weight management because of its powerful appetite-suppressing effect.
Read nutrition guide →
Wegovy
semaglutide · Once-weekly subcutaneous injection
Wegovy is a once-weekly injectable medication FDA-approved specifically for chronic weight management in adults and adolescents (12+) with obesity or overweight with at least one weight-related condition. It contains the same active ingredient as Ozempic — semaglutide — but at a higher target dose (2.4 mg/week vs Ozempic's 2 mg ceiling).
Read nutrition guide →
Zepbound
tirzepatide · Once-weekly subcutaneous injection
Zepbound is a once-weekly injectable medication FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It contains tirzepatide — the same active ingredient as Mounjaro — but is FDA-approved at the higher doses (up to 15 mg) for weight loss specifically.
Read nutrition guide →